
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc. benefits from its unique international footprint, which includes joint ventures in India and the Kingdom of Saudi Arabia, alongside strong manufacturing capabilities in the United States, enabling the company to enhance the accessibility of its high-quality molecular diagnostics. The company's proprietary technology and patented design algorithms facilitate scalability in operations, which positions Co-Diagnostics favorably within the growing molecular diagnostics market. Despite concerns regarding potential dilutive capital raises, the overall strategic partnerships and innovative capabilities suggest a robust foundation for future growth and operational success.
Bears say
Co-Diagnostics Inc. has experienced a significant downward revision in its price target, shifting from $10.00 to $3.00, which indicates increased skepticism about its financial prospects despite being higher than the recent closing price of $0.43. The company's cash position of $11 million, coupled with projected quarterly expenditures of $5 to $7 million, raises concerns about potential liquidity issues and the risk of entering a downward financing spiral. Overall, the combination of reduced price expectations and alarming cash burn rates contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares